IMI consultation on advanced therapies
Response from Prof. Christof von Kalle and Dr. Manfred Schmidt

Dear Sir or Madam,

on behalf of Prof. Christof von Kalle and Dr. Manfred Schmidt (National Center for Tumor Diseases, Heidelberg, Germany and the German Cancer Research Center, Heidelberg, Germany) I would like to add following comment to the ongoing consultation on the IMI Advanced Therapies Concept Paper:

„We would advise to consider on-/off-target specificity when discussing gene editing.” (personal capacity)

Thank you very much for your consideration.

With best regards,
Klara Gießler

Klara Gießler, PhD
Scientific Coordinator NCT
National Center for Tumor Diseases (NCT)
German Cancer Research Center (DKFZ)

NCT Heidelberg
Im Neuenheimer Feld 460
69120 Heidelberg
Germany

www.nct-heidelberg.de